References
- Holly J. Physiology of the IGF system. Novartis Foundation Symp 2004; 262: 19–35
- Firth S. M., Baxter R. C. Cellular actions of the insulin‐like growth factor binding proteins. Endocr Rev 2002; 23: 824–54
- Frystyk J., Ledet T., Moller N., Flyvbjerg A., Orskov H. Cardiovascular disease and insulin‐like growth factor I. Circulation 2002; 106: 893–5
- Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin‐like growth factor I is associated with increased risk of ischemic heart disease. A population‐based case‐control study. Circulation 2002; 106: 939–44
- Kaplan R. C., Strickler H. D., Rohan T. E., Muzumdar R., Brown D. L. Insulin‐like growth factors and coronary heart disease. Cardiol Rev 2005; 13: 35–9
- Janssen J. A., Lamberts S. W. J. The role of IGF‐I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. Eur J Endocrinol 2002; 146: 467–77
- Fischer F., Schulte H., Mohan S., Tataru M‐C., Kohler E., Assmann G., et al. Associations of insulin‐like growth factors, insulin‐like growth factor binding proteins and acid‐labile subunit with coronary heart disease. Clin Endocrinol 2004; 61: 595–602
- Ruotolo G., Bavenholm P., Brismar K., Efendic S., Ericsson C. G., de Faire U., et al. Serum insulin‐like growth factor‐I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000; 35: 647–54
- Colangelo L. A., Liu K., Gapstur S. M. Insulin‐like growth factor‐1, insulin‐like growth factor binding protein‐3 and cardiovascular disease risk factors in young black men and white men. The CARDIA male hormone study. Am J Epidemiol 2004; 160: 750–7
- Alwan A. A. Cardiovascular diseases in the eastern Mediterranean region. World Hlth Stat Q 1993; 46: 97–100
- Akanji A. O., Al‐Sulaiman A., Prabha K., Safar F., Al‐Zaid K., Mojiminiyi O. A. Profile of hyperlipidaemic patients in Kuwait: frequency of cardiovascular disease risk factors at presentation and initial response to treatment. J Kuwait Med Assoc 1997; 29: 25–33
- Akanji A. O. Apo (a) isoforms do not predict coronary heart disease risk in a Gulf Arab population. Ann Clin Biochem 2000; 37: 360–6
- Anonymous. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–97
- Alberti K. G. M. M., Zimmet P., Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–62
- Friedewald W. T., Levy R. I., Frederickson D. S. Estimation of the concentration of low‐density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
- Pacini G., Mari A. Methods for clinical assessment of insulin sensitivity and beta‐cell function. Best Pract Res Clin Endocrinol Metab 2003; 17: 302–22
- Conti E., Andreotti F., Sciahbasi A., Riccardi P., Marra G., Menini E., et al. Markedly reduced insulin‐like growth factor‐1 in the acute phase of myocardial infarction. J Am Coll Cardiol 2001; 38: 26–32
- Friberg L., Werner S., Eggertsen G., Ahnve G. Growth hormone and insulin‐like growth factor‐1 in acute myocardial infarction. Eur Heart J 2000; 21: 1547–54
- Spallarosa P., Brunelli C., Minuto F., Caruso D., Battistini M., Caponnetto S., et al. Insulin‐like growth factor‐1 and angiographically documented coronary artery disease. Am J Cardiol 1996; 77: 200–2
- Conti E., Carrozza C., Capoluongo E., Volpe M., Crea F., Zuppi C., et al. Insulin‐like growth factor‐1 as a vascular protective factor. Circulation 2004; 110: 2260–5
- Heald A., Kaushal K., Anderson S., Redpath M., Durrington P. N., Selby P. L., et al. Effects of hormone replacement therapy on insulin‐like growth factor (IGF)‐I, IGF‐II and IGF binding protein (IGFBP)‐1 to IGFBP‐4: implications for cardiovascular risk. Gynecol Endocrinol 2005; 20: 176–82